U.S. Renal Care Presents Vadadustat Study for Anemia in Hemodialysis Patients

PUBT · 10/29 12:11
U.S. Renal Care Presents Vadadustat Study for Anemia in Hemodialysis Patients
  • U.S. Renal Care announced October 29, 2026, it will present eight studies at the American Society of Nephrology’s Kidney Week 2026.
  • A real-world study associates DefenCath catheter locking solution use with reduced catheter-related bloodstream infections in dialysis centers.
  • Other presentations cover vadadustat for dialysis-related anemia, upacicalcet for secondary hyperparathyroidism, and an ongoing Phase 2b AP306 trial for hyperphosphatemia.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. U.S. Renal Care Inc. published the original content used to generate this news brief on October 29, 2026, and is solely responsible for the information contained therein.